{
    "clinical_study": {
        "@rank": "134575", 
        "arm_group": [
            {
                "arm_group_label": "Prophylaxis safety and efficacy substudy", 
                "arm_group_type": "Experimental", 
                "description": "Hemostatic efficacy of GreenGene\u2122 F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding during prophylaxis over \u2265 50 additional exposure days."
            }, 
            {
                "arm_group_label": "On-demand safety and efficacy substudy", 
                "arm_group_type": "Experimental", 
                "description": "Hemostatic efficacy of GreenGene\u2122 F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding in a minimum of 10 on demand treated subjects during additional 50 exposure days."
            }
        ], 
        "brief_summary": {
            "textblock": "This study primarily will address the safety and secondarily will assess efficacy of\n      GreenGene\u2122 F in subjects with severe hemophilia A previously  treated \u226550 exposure days with\n      a GreenGene\u2122 F, and without presence inhibitor to FVIII (Factor VIII)."
        }, 
        "brief_title": "Safety and Efficacy Extension Study of GreenGene\u2122 F in Previously Treated Patients Diagnosed With Severe Hemophilia A", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hemophilia A", 
        "condition_browse": {
            "mesh_term": "Hemophilia A"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects must have participated in the \"GreenGene\u2122 F_P3\", (with Eudra CT number\n             2012-001445-40) or a pediatric study with GreenGene\u2122 F\n\n          2. Have \u226550 previous exposure days to GreenGene\u2122 F, as documented in the subject's\n             medical records.\n\n          3. Negative assays for FVIII inhibitor at inclusion (<0.6BU Nijmegen assay), i.e. at the\n             end of study \"GreenGene\u2122 F_P3\" for patients entering into this extension study\n             immediately after finishing the previous phase III study.\n\n          4. Normal liver and kidney function\n\n          5. Platelet count \u2265 100,000\u3395\n\n          6. Normal prothrombin time or International Normalized Ratio (INR) < 1.5\n\n          7. Subjects receiving therapy for human immunodeficiency virus (HIV) or hepatitis must\n             be on a stable treatment regimen\n\n          8. Subjects must be able to withhold FVIII infusions for approximately 72 h prior to\n             each inhibitor assay\n\n          9. Absolute CD4 lymphocyte cell count \u2265 200\u3395\n\n         10. Signed the written informed consent form or informed consent was obtained from the\n             subject's legal guardian\n\n         11. Females must not be lactating or pregnant at screening or Baseline (as documented by\n             a negative beta-human chorionic gonadotropin [\u03b2-hCG] test with a minimum sensitivity\n             of 25 IU/L or equivalent units of \u03b2-hCG). A test was obtained more than 72 hours\n             before the first dose of study drug\n\n         12. All females will be considered to be of childbearing potential unless they are\n             appropriate age group and without other known or suspected cause) or have been\n             sterilized surgically (i.e. bilateral tubal ligation, total hysterectomy or bilateral\n             oophorectomy, all with surgery at least one month before dosing)\n\n         13. Willing and able to comply with all aspects of the protocol\n\n        Exclusion Criteria:\n\n          1. Presence at Screening of FVIII inhibitor \u2265 0.6 BU as tested with the Nijmegen\n             modification of the Bethesda assay.\n\n          2. Laboratory or clinical evidence of portal vein hypertension including, but not\n             limited to, an INR > 1.4, the presence of splenomegaly and/or spider angiomata of\n             physical examination and/or a history of esophageal hemorrhage or documented\n             esophageal varices\n\n          3. Uncontrolled hypertension (diastolic blood pressure >100 mm Hg)\n\n          4. Hemoglobin < 10 g/dL\n\n          5. Severe renal dysfunction (creatinine > 2x upper limit of normal [ULN], total\n             bilirubin > 2x the ULN)\n\n          6. Liver disease (alanine aminotransferase [ALT], aspartate aminotransferase [AST] > 3x\n             the ULN)\n\n          7. History of diabetes or other metabolic disease\n\n          8. History of hypersensitivity or serious adverse reaction to recombinant or\n             plasma-derived FVIII concentrates\n\n          9. History of pretreatment prior to the administration of FVIII products (e.g.,\n             antihistamines)\n\n         10. Regular use of antifibrinolytics or medications affecting platelet function\n\n         11. Hypersensitivity to hamster- or mouse derived proteins\n\n         12. Blood transfusions within 30 days of enrollment into the study\n\n         13. Current participation in another investigational drug or device study, or\n             participated in a clinical study involving an investigational drug or device within\n             30 days of enrollment into the study\n\n         14. Unable or unwilling to cooperate with study procedures\n\n         15. Females who are pregnant (positive \u03b2-hCG test) or breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02027779", 
            "org_study_id": "GreenGene\u2122 F_E_P3"
        }, 
        "intervention": [
            {
                "arm_group_label": "Prophylaxis safety and efficacy substudy", 
                "description": "Prophylaxis safety and efficacy substudy:\nintra venous infusion, 30 \u00b1 10 IU/kg infusions 3 times per week with dose escalation to 45 \u00b1 10 IU/kg if appropriate, for 50 exposure days", 
                "intervention_name": "GreenGene\u2122 F", 
                "intervention_type": "Biological", 
                "other_name": [
                    "GreenGeneF", 
                    "GreenGene F"
                ]
            }, 
            {
                "arm_group_label": "On-demand safety and efficacy substudy", 
                "description": "On-demand safety and efficacy substudy:\nminor bleed = 20 \u00b1 10 IU/kg moderate bleed = 30 \u00b1 10 IU/kg major bleed = 30 - 50 IU/kg", 
                "intervention_name": "GreenGene\u2122 F", 
                "intervention_type": "Biological", 
                "other_name": [
                    "GreenGeneF", 
                    "GreenGene F"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "GreenGene\u2122 F, Previously Treated Patients", 
        "lastchanged_date": "January 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "WarrenBryceA@uams.edu", 
                    "last_name": "Bryce Warren", 
                    "phone": "501-364-4003"
                }, 
                "facility": {
                    "address": {
                        "city": "Little Rock", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72202"
                    }, 
                    "name": "Arkansas Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Kimo Stine, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Pmurray1@nshs.edu", 
                    "last_name": "Patricia Murray", 
                    "phone": "718-470-7380"
                }, 
                "contact_backup": {
                    "email": "lpatriar@nshs.edu", 
                    "last_name": "Lisa Patriarca", 
                    "phone": "718 470 7380"
                }, 
                "facility": {
                    "address": {
                        "city": "New Hyde Park", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11040"
                    }, 
                    "name": "Long Island Jewish Medical Center - Hemophilia Treatment Center"
                }, 
                "investigator": {
                    "last_name": "Richard Lipton, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open Label Safety and Efficacy Extension Study of GreenGene\u2122 F in Previously Treated Patients Diagnosed With Severe Hemophilia A", 
        "overall_contact": {
            "email": "chleedr@greencross.com", 
            "last_name": "Chang Hee Lee, M.D.", 
            "phone": "+82 31 260 9729"
        }, 
        "overall_contact_backup": {
            "email": "kwait@atlanticresearchgroup.com", 
            "last_name": "Kevin Wait", 
            "phone": "+1 540 649 5490"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Development of neutralizing antibodies (inhibitors) will be followed during the regular visits, average of 3 months.", 
            "measure": "Number of subjects with development of inhibitors", 
            "safety_issue": "Yes", 
            "time_frame": "every 3 months, up to 18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02027779"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Green Cross Corporation", 
        "sponsors": {
            "collaborator": {
                "agency": "Atlantic Research Group", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Green Cross Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}